Judith KOUASSI NZOUGHET

Dr. Judith KOUASSI NZOUGHET

Faculté de Pharmacie, University Paris Cité, Paris, France
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Helene BlascoHelene Blasco
Helene Blasco
CVC. Veyrat-Durebex
C. Veyrat-Durebex
CBC. Bocca
C. Bocca
FPF. Patin
F. Patin
PVP. Vourc’h
P. Vourc’h
PRPascal Reynier
Pascal Reynier
Amyotrophic lateral sclerosis (ALS), the commonest adult-onset motor neuron disorder, is characterized by a survival span of only 2–5 years after onset. Relevant biomarkers or specific metabolic signatures would provide powerful tools for the management of ALS. The main objective of this study was to investigate the cerebrospinal fluid (CSF) lipidomic signature of ALS patients by mass spectrometry to evaluate the diagnostic and predictive values of the profile. We showed that ALS patients (n = 40) displayed a highly significant specific CSF lipidomic signature compared to controls (n = 45). Phosphatidylcholine PC(36:4), higher in ALS patients (p = 0.0003) was the most discriminant molecule, and ceramides and glucosylceramides were also highly relevant. Analysis of targeted lipids in the brain cortex of ALS model mice confirmed the role of some discriminant lipids such as PC. We also obtained good models for predicting the variation of the ALSFRS-r score from the lipidome baseline, with an accuracy of 71% in an independent set of patients. Significant predictions of clinical evolution were found to be correlated to sphingomyelins and triglycerides with long-chain fatty acids. Our study, which shows extensive lipid remodelling in the CSF of ALS patients, provides a new metabolic signature of the disease and its evolution with good predictive performance.

3 June 2019 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
Judith KOUASSI NZOUGHETJudith KOUASSI NZOUGHET
Judith KOUASSI NZOUGHET
JBJuan Manuel Chao de la Barca
Juan Manuel Chao de la Barca
KGKhadidja Guehlouz
Khadidja Guehlouz
SLStéphanie Leruez
Stéphanie Leruez
LCLaurent Coulbault
Laurent Coulbault
PRPascal Reynier
Pascal Reynier
Purpose: To investigate the plasma concentration of nicotinamide in primary open-angle glaucoma (POAG). Methods: Plasma of 34 POAG individuals was compared to that of 30 age- and sex-matched controls using a semiquantitative method based on liquid chromatography coupled to high-resolution mass spectrometry. Subsequently, an independent quantitative method, based on liquid chromatography coupled to mass spectrometry, was used to assess nicotinamide concentration in the plasma from the same initial cohort and from a replicative cohort of 20 POAG individuals and 15 controls. Results: Using the semiquantitative method, the plasma nicotinamide concentration was significantly lower in the initial cohort of POAG individuals compared to controls and further confirmed in the same cohort, using the targeted quantitative method, with mean concentrations of 0.14 μM (median: 0.12 μM; range, 0.06–0.28 μM) in the POAG group (−30%; P = 0.022) and 0.19 μM (median: 0.18 μM; range, 0.08–0.47 μM) in the control group. The quantitative dosage also disclosed a significantly lower plasma nicotinamide concentration (−33%; P = 0.011) in the replicative cohort with mean concentrations of 0.14 μM (median: 0.14 μM; range, 0.09–0.25 μM) in the POAG group, and 0.19 μM (median: 0.21 μM; range, 0.09–0.26 μM) in the control group. Conclusions: Glaucoma is associated with lower plasmatic nicotinamide levels, compared to controls, suggesting that nicotinamide supplementation might become a future therapeutic strategy. Further studies are needed, in larger cohorts, to confirm these preliminary findings.

1 March 2020 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
LPLéa Paolini
Léa Paolini
CAClément Adam
Clément Adam
CBCéline Beauvillain
Céline Beauvillain
LPLaurence Preisser
Laurence Preisser
SBSimon Blanchard
Simon Blanchard
PJPascale Jeannin
Pascale Jeannin
In established tumors, tumor-associated macrophages (TAM) orchestrate nonresolving cancer-related inflammation and produce mediators favoring tumor growth, metastasis, and angiogenesis. However, the factors conferring inflammatory and protumor properties on human macrophages remain largely unknown. Most solid tumors have high lactate content. We therefore analyzed the impact of lactate on human monocyte differentiation. We report that prolonged lactic acidosis induces the differentiation of monocytes into macrophages with a phenotype including protumor and inflammatory characteristics. These cells produce tumor growth factors, inflammatory cytokines, and chemokines as well as low amounts of IL10. These effects of lactate require its metabolism and are associated with hypoxia-inducible factor-1α stabilization. The expression of some lactate-induced genes is dependent on autocrine M-CSF consumption. Finally, TAMs with protumor and inflammatory characteristics (VEGFhigh CXCL8+ IL1β+) are found in solid ovarian tumors. These results show that tumor-derived lactate links the protumor features of TAMs with their inflammatory properties. Treatments that reduce tumor glycolysis or tumor-associated acidosis may help combat cancer.

6 January 2017 in Analytical Chemistry
Verified
Journal Article
Closed access
Judith KOUASSI NZOUGHETJudith KOUASSI NZOUGHET
Judith KOUASSI NZOUGHET
CBCinzia Bocca
Cinzia Bocca
GSGilles Simard
Gilles Simard
DPDelphine Prunier-Mirebeau
Delphine Prunier-Mirebeau
JBJuan Manuel Chao de la Barca
Juan Manuel Chao de la Barca
PRPascal Reynier
Pascal Reynier

15 September 2016 in Brain
Verified
Journal Article
Open access
PDF file
JBJuan Manuel Chao de la Barca
Juan Manuel Chao de la Barca
GSGilles Simard
Gilles Simard
PAPatrizia Amati-Bonneau
Patrizia Amati-Bonneau
ZSZainab Safiedeen
Zainab Safiedeen
DPDelphine Prunier-Mirebeau
Delphine Prunier-Mirebeau
PRPascal Reynier
Pascal Reynier
Leber’s hereditary optic neuropathy (MIM#535000), the commonest mitochondrial DNA-related disease, is caused by mutations affecting mitochondrial complex I. The clinical expression of the disorder, usually occurring in young adults, is typically characterized by subacute, usually sequential, bilateral visual loss, resulting from the degeneration of retinal ganglion cells. As the precise action of mitochondrial DNA mutations on the overall cell metabolism in Leber’s hereditary optic neuropathy is unknown, we investigated the metabolomic profile of the disease. High performance liquid chromatography coupled with tandem mass spectrometry was used to quantify 188 metabolites in fibroblasts from 16 patients with Leber’s hereditary optic neuropathy and eight healthy control subjects. Latent variable-based statistical methods were used to identify discriminating metabolites. One hundred and twenty-four of the metabolites were considered to be accurately quantified. A supervised orthogonal partial least squares discriminant analysis model separating patients with Leber’s hereditary optic neuropathy from control subjects showed good predictive capability (Q2cumulated = 0.57). Thirty-eight metabolites appeared to be the most significant variables, defining a Leber’s hereditary optic neuropathy metabolic signature that revealed decreased concentrations of all proteinogenic amino acids, spermidine, putrescine, isovaleryl-carnitine, propionyl-carnitine and five sphingomyelin species, together with increased concentrations of 10 phosphatidylcholine species. This signature was not reproduced by the inhibition of complex I with rotenone or piericidin A in control fibroblasts. The importance of sphingomyelins and phosphatidylcholines in the Leber’s hereditary optic neuropathy signature, together with the decreased amino acid pool, suggested an involvement of the endoplasmic reticulum. This was confirmed by the significantly increased phosphorylation of PERK and eIF2α, as well as the greater expression of C/EBP homologous protein and the increased XBP1 splicing, in fibroblasts from affected patients, all these changes being reversed by the endoplasmic reticulum stress inhibitor, TUDCA (tauroursodeoxycholic acid). Thus, our metabolomic analysis reveals a pharmacologically-reversible endoplasmic reticulum stress in complex I-related Leber’s hereditary optic neuropathy fibroblasts, a finding that may open up new therapeutic perspectives for the treatment of Leber’s hereditary optic neuropathy with endoplasmic reticulum-targeting drugs.

28 January 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
Judith KOUASSI NZOUGHETJudith KOUASSI NZOUGHET
Judith KOUASSI NZOUGHET
KGKhadidja Guehlouz
Khadidja Guehlouz
SLStéphanie Leruez
Stéphanie Leruez
PGPhilippe Gohier
Philippe Gohier
CBCinzia Bocca
Cinzia Bocca
PRPascal Reynier
Pascal Reynier
Glaucoma is an age related disease characterized by the progressive loss of retinal ganglion cells, which are the neurons that transduce the visual information from the retina to the brain. It is the leading cause of irreversible blindness worldwide. To gain further insights into primary open-angle glaucoma (POAG) pathophysiology, we performed a non-targeted metabolomics analysis on the plasma from POAG patients (n = 34) and age- and sex-matched controls (n = 30). We investigated the differential signature of POAG plasma compared to controls, using liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS). A data mining strategy, combining a filtering method with threshold criterion, a wrapper method with iterative selection, and an embedded method with penalization constraint, was used. These strategies are most often used separately in metabolomics studies, with each of them having their own limitations. We opted for a synergistic approach as a mean to unravel the most relevant metabolomics signature. We identified a set of nine metabolites, namely: nicotinamide, hypoxanthine, xanthine, and 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline with decreased concentrations and N-acetyl-L-Leucine, arginine, RAC-glycerol 1-myristate, 1-oleoyl-RAC-glycerol, cystathionine with increased concentrations in POAG; the modification of nicotinamide, N-acetyl-L-Leucine, and arginine concentrations being the most discriminant. Our findings open up therapeutic perspectives for the diagnosis and treatment of POAG.